Zheng Yan, Xu Chu, Jin Yan
Department of Endocrinology, Zhoushan Hospital, Zhejiang Province, Zhoushan, Zhejiang, China.
Front Endocrinol (Lausanne). 2024 Dec 3;15:1398382. doi: 10.3389/fendo.2024.1398382. eCollection 2024.
This systematic review and meta-analysis aimed to synthesize the role of exosomes in the pathogenesis and management of diabetic kidney disease.
PubMed, Embase, Cochrane Library, and Web of Science were searched for studies that compared the levels of exosomes between patients with diabetic kidney disease and controls published up to 27 November 2023. Methodological quality was assessed using the JBI Appraisal Checklist for Case-Control Studies. The methodology of the samples and the main results were summarized. A meta-analysis of the diagnostic performance of exosomes was performed using estimates of test sensitivity and specificity, and these values were summarized using summary receiver-operating characteristic curves. The results were reported following the PRISMA 2020 checklist.
A total of 32 studies, including 1,119 patients with diabetic kidney disease and 1,328 controls, met the inclusion criteria. A total of 78 upregulated and 22 downregulated microRNAs, 2 upregulated and 4 downregulated mRNAs, 6 upregulated and 1 downregulated proteins, and 4 upregulated lipids were identified. The miR-126, miR-145, miR-150, miR-21, and WT1 mRNA dysregulation were consistently reported in at least two studies. The overall sensitivity and specificity of the exosomes in diabetic kidney disease diagnosis were 0.70 (95% CI: 0.59-0.80) and 0.79 (95% CI: 0.70-0.85), respectively. The summary receiver operating characteristic curve was plotted to assess diagnostic accuracy with the area under the curve (AUC) of 0.82 (95% CI: 0.78-0.85).
Exosomes have great potential to become effective diagnostic biomarkers for diabetic kidney disease. Panels of exosomes or the combination of exosomes with other clinical indicators seemed more accurate than single exosomes.
本系统评价和荟萃分析旨在综合外泌体在糖尿病肾病发病机制及治疗中的作用。
检索了PubMed、Embase、Cochrane图书馆和Web of Science,查找截至2023年11月27日发表的比较糖尿病肾病患者和对照组外泌体水平的研究。使用JBI病例对照研究评估清单评估方法学质量。总结了样本的方法和主要结果。使用测试敏感性和特异性估计值对外泌体的诊断性能进行荟萃分析,并使用汇总的受试者工作特征曲线总结这些值。结果按照PRISMA 2020清单进行报告。
共有32项研究符合纳入标准,包括1119例糖尿病肾病患者和1328例对照。共鉴定出78种上调和22种下调的微小RNA、2种上调和4种下调的信使RNA、6种上调和1种下调的蛋白质以及4种上调的脂质。至少两项研究一致报道了miR-126、miR-145、miR-150、miR-21和WT1信使RNA的失调。外泌体在糖尿病肾病诊断中的总体敏感性和特异性分别为0.70(95%CI:0.59 - 0.80)和0.79(95%CI:0.70 - 0.85)。绘制汇总受试者工作特征曲线以评估诊断准确性,曲线下面积(AUC)为0.82(95%CI:0.78 - 0.85)。
外泌体有很大潜力成为糖尿病肾病有效的诊断生物标志物。外泌体组合或外泌体与其他临床指标的联合似乎比单一外泌体更准确。